Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic …
Biotechnology
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
Metric | Q4 | Q1 | Δ in % | |
---|---|---|---|---|
Current Ratio | 2.97 | 3.17 | 3.08 | |
Debt/Assets | n.A. | n.A. | n.A. | |
Debt/Equity | n.A. | n.A. | n.A. | |
Net Debt/EBITDA | -268.39 | -66.93 | -18.17 | |
Naive Interpretation | member |
2
Per Share
Metric | Q4 | Q1 | Δ in % | |
---|---|---|---|---|
Book Value | 1.04 | -1.74 | -1.76 | |
Cash | -3.20 | 18.80 | 19.42 | |
Capex | 15.61 | -0.10 | -0.12 | |
Free Cash Flow | -108.62 | -0.75 | -0.36 | |
Revenue | 11.95 | 3.92 | 3.50 | |
Naive Interpretation | member |
3
Profitability
Metric | Q4 | Q1 | Δ in % | |
---|---|---|---|---|
Gross Margin | 7.68 | 0.87 | 0.80 | |
Operating Margin | 66.81 | -0.09 | -0.26 | |
ROA | 52.11 | -0.02 | -0.04 | |
ROE | -51.88 | 0.30 | 0.62 | |
ROIC | 61.50 | -0.02 | -0.05 | |
Naive Interpretation | member |
4
Valuation
The "Valuation Entry" for the Focus of ALNY is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ALNY is permitted for members.
6
Leverage & Liquidity